MCID: PHB001
MIFTS: 38

Phobic Disorder

Categories: Mental diseases

Aliases & Classifications for Phobic Disorder

MalaCards integrated aliases for Phobic Disorder:

Name: Phobic Disorder 12 15
Phobic Anxiety Disorder 73
Phobic Disorders 44

Classifications:



External Ids:

Disease Ontology 12 DOID:591
ICD10 33 F40 F40.9
ICD9CM 35 300.2 300.20
MeSH 44 D010698
NCIt 50 C35420
SNOMED-CT 68 52039009 65673007
UMLS 73 C0349231

Summaries for Phobic Disorder

Disease Ontology : 12 An anxiety disorder where fear and anxiety are triggered by a specific stimulus or situation.

MalaCards based summary : Phobic Disorder, also known as phobic anxiety disorder, is related to social phobia and phobia, specific. An important gene associated with Phobic Disorder is MAOA (Monoamine Oxidase A), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Serotonergic synapse. The drugs Vortioxetine and Paroxetine have been mentioned in the context of this disorder. Related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 76 A phobia is a type of anxiety disorder, defined by a persistent and excessive fear of an object or... more...

Related Diseases for Phobic Disorder

Diseases related to Phobic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Related Disease Score Top Affiliating Genes
1 social phobia 31.7 HTR1A MAOA SLC6A4
2 phobia, specific 31.3 COMT MAOA NBAS
3 agoraphobia 30.8 GLRB HTR1A MAOA OPRK1 PIR PTK7
4 substance dependence 30.0 MAOA OPRK1 SLC6A4
5 schizophrenia 29.8 COMT HTR1A MAOA SLC6A4
6 anxiety 29.7 COMT HTR1A MAOA PTK7 SLC6A4
7 panic disorder 28.8 COMT GLRB HTR1A MAOA PTK7 RGS2
8 avoidant personality disorder 10.2 MAOA SLC6A4
9 atypical depressive disorder 10.2 MAOA SLC6A4
10 schizoid personality disorder 10.2 HTR1A PIR
11 dependent personality disorder 10.2 MAOA PIR
12 psychosexual disorder 10.2 HTR1A SLC6A4
13 sexual disorder 10.2 HTR1A SLC6A4
14 pathological gambling 10.2 MAOA SLC6A4
15 periodic limb movement disorder 10.1 HTR1A SLC6A4
16 intermittent explosive disorder 10.1 HTR1A SLC6A4
17 dysthymic disorder 10.1 MAOA PIR SLC6A4
18 neurotic disorder 10.1 GLRB HTR1A
19 depression 10.1 HTR1A MAOA SLC6A4
20 kleptomania 10.1 HTR1A MAOA SLC6A4
21 serotonin syndrome 10.1 HTR1A MAOA SLC6A4
22 endogenous depression 10.1 HTR1A MAOA SLC6A4
23 migraine without aura 10.1 HTR1A SLC6A4
24 opiate dependence 10.0 OPRK1 SLC6A4
25 sudden infant death syndrome 10.0 HTR1A MAOA SLC6A4
26 separation anxiety disorder 10.0 NBAS PIR
27 dyspepsia 10.0 HTR1A SLC6A4
28 neonatal abstinence syndrome 10.0 COMT OPRK1
29 dystonia 1, torsion, autosomal dominant 9.9 COMT MAOA
30 oppositional defiant disorder 9.9 COMT MAOA SLC6A4
31 cocaine dependence 9.9 OPRK1 SLC6A4
32 fibromyalgia 9.9 COMT SLC6A4
33 opioid addiction 9.9 COMT OPRK1
34 antisocial personality disorder 9.9 COMT MAOA SLC6A4
35 paranoid schizophrenia 9.9 COMT MAOA SLC6A4
36 postpartum depression 9.9 COMT MAOA SLC6A4
37 anorexia nervosa 9.9
38 conduct disorder 9.9 COMT MAOA SLC6A4
39 substance abuse 9.9 COMT MAOA SLC6A4
40 post-traumatic stress disorder 9.9 COMT MAOA SLC6A4
41 premature ejaculation 9.9 COMT HTR1A SLC6A4
42 tobacco addiction 9.9 COMT MAOA SLC6A4
43 alexithymia 9.9 COMT HTR1A SLC6A4
44 bipolar i disorder 9.9 COMT HTR1A SLC6A4
45 psychotic disorder 9.9 COMT HTR1A SLC6A4
46 brunner syndrome 9.8 COMT HTR1A MAOA SLC6A4
47 borderline personality disorder 9.8 COMT HTR1A MAOA SLC6A4
48 personality disorder 9.8 COMT HTR1A MAOA SLC6A4
49 mental depression 9.8 COMT HTR1A MAOA SLC6A4
50 chronic fatigue syndrome 9.8 COMT HTR1A MAOA SLC6A4

Graphical network of the top 20 diseases related to Phobic Disorder:



Diseases related to Phobic Disorder

Symptoms & Phenotypes for Phobic Disorder

MGI Mouse Phenotypes related to Phobic Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.7 COMT GLRB HTR1A MAOA OPRK1 RGS2
2 cardiovascular system MP:0005385 9.5 COMT GLRB HTR1A MAOA PTK7 RGS2
3 nervous system MP:0003631 9.23 COMT GLRB HTR1A MAOA OPRK1 PTK7

Drugs & Therapeutics for Phobic Disorder

Drugs for Phobic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 259)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
2
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61869-08-7 43815
3
Cycloserine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 68-41-7 6234 401
4
Norepinephrine Approved Phase 4,Phase 3,Not Applicable 51-41-2 439260
5
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 59729-33-8 2771
6
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
7
Sertraline Approved Phase 4,Phase 3,Phase 2,Not Applicable 79617-96-2 68617
8
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
9 Piracetam Approved, Investigational Phase 4,Phase 2 7491-74-9
10
Tiagabine Approved, Investigational Phase 4 115103-54-3 60648
11
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
12
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
13
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
14
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
15
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 525-66-6 4946
16
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 137-58-6 3676
17
Tetracaine Approved, Vet_approved Phase 4,Phase 2 94-24-6 5411
18
Topiramate Approved Phase 4 97240-79-4 5284627
19 Mirabegron Approved Phase 4 223673-61-8
20
Acetylcholine Approved Phase 4 51-84-3 187
21 Etiracetam Investigational Phase 4,Phase 2 33996-58-6
22 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
23 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Serotonin Antagonists Phase 4,Phase 2
25 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
27 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
28 Serotonin Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
29 Serotonin 5-HT1 Receptor Agonists Phase 4,Not Applicable
30 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
31 Serotonin Uptake Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 Serotonin 5-HT3 Receptor Antagonists Phase 4
33 Antidepressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
34 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
36 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Anti-Infective Agents, Urinary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Renal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Venlafaxine Hydrochloride Phase 4,Phase 3
45 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4,Phase 3
46 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
47 Parasympatholytics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
48 Cholinergic Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
49 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
50 Muscarinic Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 480)
# Name Status NCT ID Phase Drugs
1 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Unknown status NCT02294305 Phase 4 Vortioxetine;Placebo
2 The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Public Speaking Environment Completed NCT00407199 Phase 4 quetiapine
3 RCT of Cognitive Therapy, Paroxetine, Combined CT and Paroxetine and Placebo Completed NCT00184106 Phase 4 Seroxat, Cognitive therapy, Seroxat+ cognitive therapy
4 D-Cycloserine Enhancement of Exposure in Social Phobia Completed NCT00633984 Phase 4 D-Cycloserine;Placebo
5 Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder Completed NCT00282828 Phase 4 Sertraline;Venlafaxine;Placebo;Clonazepam
6 Nefazodone in the Treatment of Social Phobia Completed NCT00231348 Phase 4 Nefazodone
7 Comparison of Routine IM Influenza Immunization and Administration by Jet-injector (Med-Jet H4™) in Healthy Young Adults Completed NCT03150537 Phase 4
8 12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder Completed NCT01316302 Phase 4 Pristiq;Placebo
9 Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder Completed NCT00265109 Phase 4 Levetiracetam
10 Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder Completed NCT00208741 Phase 4 Gabitril
11 Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism Completed NCT00246441 Phase 4 Paroxetine;Placebo
12 Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder Completed NCT00767871 Phase 4 Lexapro
13 Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults Completed NCT01224067 Phase 4 Quetiapine
14 Escitalopram in Patients With Social Anxiety Disorder Completed NCT00902226 Phase 4 Escitalopram
15 Phase 4 Study to Evaluate Efficacy of Paliperidone Extended-Release(ER) in Schizophrenic Participants Completed NCT00761605 Phase 4 Paliperidone
16 Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety Completed NCT00177008 Phase 4 Aripiprazole
17 Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder Completed NCT00190879 Phase 4 Atomoxetine hydrochloride;placebo
18 Primary Care Intervention Strategy for Anxiety Disorders Completed NCT00347269 Phase 4 Psychotropic medication optimization
19 Acamprosate in Alcoholics With Comorbid Anxiety or Depression Completed NCT00330174 Phase 4 Acamprosate
20 The Study of Cognitive Rehabilitation Effectiveness for Mild Traumatic Brain Injury Completed NCT01339806 Phase 4
21 Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants Completed NCT00784238 Phase 4 Paliperidone
22 Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity Completed NCT01863459 Phase 4 Lisdexamfetamine Dimesylate;placebo
23 Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission Completed NCT00761579 Phase 4 Paliperidone
24 Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD) Completed NCT00560612 Phase 4 Paroxetine;Placebo
25 Efficacy of Adding Topiramate to Current Treatment in Treatment-Resistant Generalized Social Phobia (GSP) Recruiting NCT00182455 Phase 4 Topiramate;Placebo
26 Treatments for Anxiety: Meditation and Escitalopram Recruiting NCT03522844 Phase 4 Escitalopram
27 The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals Recruiting NCT02536846 Phase 4 Olanzapine
28 Brief Intervention to Reduce Fear of Public Speaking Active, not recruiting NCT02790736 Phase 4 propranolol;Placebo
29 A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) Active, not recruiting NCT03348618 Phase 4
30 Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome Not yet recruiting NCT03695822 Phase 4 Mirabegron 25mg
31 A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity Not yet recruiting NCT03785223 Phase 4 Methylphenidate Hydrochloride Controlled-Release Capsules;Placebo Capsule
32 Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias Terminated NCT01623583 Phase 4
33 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Terminated NCT00182533 Phase 4 Sertraline;Placebo
34 A Study of the Efficacy of Botox in the Treatment of Social Anxiety Disorder Terminated NCT03078270 Phase 4 botulinum toxin A
35 Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice Unknown status NCT01388231 Phase 2, Phase 3
36 Study of Escitalopram in the Treatment of Specific Phobia Completed NCT00121069 Phase 2, Phase 3 Escitalopram
37 Treatment of Childhood Social Phobia Completed NCT00043537 Phase 3 Fluoxetine;Pill Placebo
38 Residential Cognitive and Interpersonal Therapy for Social Phobia Completed NCT00326430 Phase 2, Phase 3
39 A Comparison Between Internet Therapy and Group Therapy for Social Phobia - A Trial Using Cognitive Behavioural Therapy Completed NCT00564967 Phase 3
40 Treatment of Social Phobia and Panic Disorder in Adults Completed NCT00619138 Phase 3
41 Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia Completed NCT00515879 Phase 3 D-cycloserine;Placebo
42 Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety Completed NCT00958880 Phase 3 Yohimbine Hydrochloride;Sugar Pill
43 D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia Completed NCT01102803 Phase 3 D-Cycloserine;Placebo
44 Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants Completed NCT00734422 Phase 2, Phase 3
45 Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants Completed NCT02007694 Phase 2, Phase 3
46 Long-term Study Of Paroxetine in Women and Men Completed NCT00264654 Phase 3 BRL29060A;paroxetine hydrochloride hydrate
47 Social Anxiety Disorder Study Of Paroxetine Completed NCT00318669 Phase 3 Paroxetine hydrochloride hydrate
48 Flushing in Social Anxiety Disorder on Seroquel Completed NCT00773162 Phase 3 Seroquel;Sugar Pill
49 Child and Adolescent Anxiety Disorders (CAMS) Completed NCT00052078 Phase 3 Sertraline (SRT);Placebo
50 Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder Completed NCT00260533 Phase 2, Phase 3 atomoxetine;placebo

Search NIH Clinical Center for Phobic Disorder

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: phobic disorders

Genetic Tests for Phobic Disorder

Anatomical Context for Phobic Disorder

Publications for Phobic Disorder

Articles related to Phobic Disorder:

# Title Authors Year
1
Choking Phobia : An Uncommon Phobic Disorder, Treated with Behavior Therapy : A Case Report and Review of the Literature. ( 28638212 )
2016
2
The effectiveness of anxiety treatment on alcohol-dependent patients with a comorbid phobic disorder: a randomized controlled trial. ( 15897725 )
2005
3
[Obsessive-phobic disorder typology in schizophrenia]. ( 11915702 )
2002
4
Familial and personal handedness in phobic anxiety disorder. ( 11960091 )
2002
5
Social and personal resources and the prevalence of phobic disorder in a community population. ( 10883724 )
2000
6
The longitudinal study of phobic disorder in a community sample from early to late adolescence. ( 11018436 )
2000
7
Phobic disorder, psychotherapy, and risk-taking: an economic perspective. ( 10180917 )
1998
8
Frequency of phobic disorder in a community sample of young adolescents. ( 7559315 )
1995
9
Is anorexia nervosa a phobic disorder? A psychophysiological enquiry. ( 7417632 )
1980

Variations for Phobic Disorder

Copy number variations for Phobic Disorder from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 94765 15 70400000 76100000 Copy number LOXL1 phobic disorder

Expression for Phobic Disorder

Search GEO for disease gene expression data for Phobic Disorder.

Pathways for Phobic Disorder

GO Terms for Phobic Disorder

Cellular components related to Phobic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.35 GLRB HTR1A OPRK1 PTK7 SLC6A4
2 integral component of presynaptic membrane GO:0099056 9.26 OPRK1 SLC6A4
3 integral component of postsynaptic membrane GO:0099055 9.16 OPRK1 SLC6A4
4 dendrite GO:0030425 8.92 COMT GLRB HTR1A OPRK1

Biological processes related to Phobic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.58 GLRB HTR1A OPRK1
2 regulation of sensory perception of pain GO:0051930 9.37 COMT OPRK1
3 vasoconstriction GO:0042310 9.32 HTR1A SLC6A4
4 catecholamine metabolic process GO:0006584 9.26 COMT MAOA
5 neurotransmitter catabolic process GO:0042135 9.16 COMT MAOA
6 behavior GO:0007610 8.96 HTR1A OPRK1
7 dopamine catabolic process GO:0042420 8.62 COMT MAOA

Molecular functions related to Phobic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serotonin binding GO:0051378 8.62 HTR1A SLC6A4

Sources for Phobic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....